Literature DB >> 31468086

[Contrast medium-induced renal failure : Useful protective measures prior to contrast medium administration].

J Wiora1, R Westenfeld2.   

Abstract

BACKGROUND: Iodinated contrast is essential for diagnosis and treatment in contemporary interventional cardiology. An important complication of percutaneous intervention is contrast-induced nephropathy, which is associated with increased morbidity and mortality, while prolonged hospitalization is responsible for economic consequences.
OBJECTIVES: This article reviews the definition of contrast-induced nephropathy, the role of biomarkers in early diagnosis to identify high-risk patients and potential therapeutic options for preventing acute nephropathy. CURRENT DATA: The optimization of patients' circulating volume remains the main aspect for preventing contrast-induced nephropathy, as recent studies confirm. Several medications are known to be nephrotoxic, whereas several are nephroprotective and the subject of recent research.
CONCLUSION: Interventions to improve outcomes of established acute kidney injury have not been developed as yet. Prevention and early diagnosis are relevant factors in clinical management. It is important to identify patients at risk and to treat them preemptively.

Entities:  

Keywords:  Acute kidney injury; Biomarkers; Contrast agent; Percutaneous coronary intervention; Prevention; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 31468086     DOI: 10.1007/s00108-019-0651-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

Review 1.  N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.

Authors:  Steven Fishbane; John H Durham; Kevin Marzo; Michael Rudnick
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

2.  Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography.

Authors:  Garvan C Kane; Brendan J Doyle; Amir Lerman; Gregory W Barsness; Patricia J Best; Charanjit S Rihal
Journal:  J Am Coll Cardiol       Date:  2008-01-01       Impact factor: 24.094

3.  Feasibility study of the RenalGuard™ balanced hydration system: a novel strategy for the prevention of contrast-induced nephropathy in high risk patients.

Authors:  Jean-Francois Dorval; Simon R Dixon; Richard B Zelman; Charles J Davidson; Robert Rudko; Frederic S Resnic
Journal:  Int J Cardiol       Date:  2011-12-26       Impact factor: 4.164

4.  Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials.

Authors:  Peter A McCullough; Patrizio Capasso
Journal:  BMC Med Imaging       Date:  2011-05-24       Impact factor: 1.930

5.  Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.

Authors:  Beth A Bartholomew; Kishore J Harjai; Srinivas Dukkipati; Judith A Boura; Michael W Yerkey; Susan Glazier; Cindy L Grines; William W O'Neill
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

6.  Serious renal dysfunction after percutaneous coronary interventions can be predicted.

Authors:  Jeremiah R Brown; James T DeVries; Winthrop D Piper; John F Robb; Michael J Hearne; Peter M Ver Lee; Mirle A Kellet; Mathew W Watkins; Thomas J Ryan; M Theodore Silver; Cathy S Ross; Todd A MacKenzie; Gerald T O'Connor; David J Malenka
Journal:  Am Heart J       Date:  2007-11-26       Impact factor: 4.749

7.  Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency.

Authors:  Wolfgang Huber; Chrysantha Schipek; Kathrin Ilgmann; Michael Page; Michael Hennig; Annette Wacker; Ursula Schweigart; Leopoldo Lutilsky; Christian Valina; Melchior Seyfarth; Albert Schömig; Meinhard Classen
Journal:  Am J Cardiol       Date:  2003-05-15       Impact factor: 2.778

8.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.

Authors:  Roxana Mehran; Eve D Aymong; Eugenia Nikolsky; Zoran Lasic; Ioannis Iakovou; Martin Fahy; Gary S Mintz; Alexandra J Lansky; Jeffrey W Moses; Gregg W Stone; Martin B Leon; George Dangas
Journal:  J Am Coll Cardiol       Date:  2004-10-06       Impact factor: 24.094

9.  Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Authors:  Linda F Fried; William Duckworth; Jane Hongyuan Zhang; Theresa O'Connor; Mary Brophy; Nicholas Emanuele; Grant D Huang; Peter A McCullough; Paul M Palevsky; Stephen Seliger; Stuart R Warren; Peter Peduzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 8.237

10.  Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention.

Authors:  Warren K Laskey; Charles Jenkins; Faith Selzer; Oscar C Marroquin; Robert L Wilensky; Ruchira Glaser; Howard A Cohen; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2007-07-30       Impact factor: 24.094

View more
  2 in total

1.  Risk factors for acute renal injury caused by contrast media after percutaneous coronary intervention and coronary angiography: A protocol for systematic review and meta-analysis.

Authors:  Junhuan Hou; Guanghua Cao; Junling Liu; Li Cai; Li Zhao; Xue Li
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

2.  Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients.

Authors:  Bin Yi; Shaoyan Mo; Yumei Jiang; Dingwu Yi; Jinwen Luo; Xiang Chen; Jian Rong
Journal:  J Interv Cardiol       Date:  2020-09-04       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.